The pharmaceutical industry of the European Union is currently toiling at a veritably Herculean task. They jointly took up the fight against falsified pharmaceuticals in the legal supply chain. Forgers have discovered that falsified drugs are a lucrative business. However, the EU legislature has recognised this risk, and responded by passing the Falsified Medicines Directive in 2011. In 2016, it was put in more concrete terms with the delegated regulation, which stipulates the implementation of the directive for prescription drugs.
Europe’s shield against falsified medicines
OpinionThe pharmaceutical industry of the European Union is currently toiling at a veritably Herculean task. They jointly took up the fight against falsified pharmaceuticals in the legal supply chain. Forgers have discovered that falsified drugs are a lucrative business. However, the EU legislature has recognised this risk, and responded by passing the Falsified Medicines Directive in 2011. In 2016, it was put in more concrete terms with the delegated regulation, which stipulates the implementation of the directive for prescription drugs.
BerGenBio plans IPO and partners with MSD
Latest NewsNorwegian BerGenBio ASA said it will go public at Oslo Børs and partnered with Merck & Co. for conducting Phase II combination studies of its oral Axl kinase blocker BGB324 with Merck’s PD-1 inhibitor pembrolizumab in lung cancer patients.
Next Big Thing in insurance: Digitalising Health
BackgroundTo date, insurance business models have always been based on damage control, but that paradigm is changing. Some insurers are now trying to hedge bets by motivating customers to get healthier and track that progress with the help of technology. Critics are concerned about data protection issues, and see this as a first step towards individualised premiums that will erode the principle of solidarity. What are the potential upsides and downsides for customers and societies?
Breath Therapeutics cashes in €43,5m
Latest NewsInhaled lung therapeutics specialist Breath Therapeutics Holding BV closed a Series A financing led by Gimv and Sofinnova.
PwC reports high productivity of UK Life Sciences
Latest NewsThe UK’s Life Sciences sector is more than twice as productive as the UK average, says a new analyst report. However, it doesn’t come close to the productivity in Switzerland or other leading life sciences clusters.
Roche restarts pivotal Gantenerumab tests
Latest NewsMorphoSys AG has announced that its partner Roche plans to start two further pivotal Phase III studies with its licensed Alzheimer’s antibody Gantenerumab.
Sanofi and AZ ink €600m deal for RSV jab
Latest NewsSanofi’s vaccine arm Sanofi Pasteur has inked a deal with AstraZeneca’s biologics subsidiary MedImmune totaling €615m to acquire co-development rights for MEDI8897, a jab to prevent respiratory syncytial virus (RSV) infection, the most common cause of lung inflammation in infants.
Nanobiotix: Oncology expert
AppointmentsThe nanomedicine specialist Nanobiotix announced ex-Novartis industry veteran Alain Dostie as new Chief Operating Officer.
Galapagos: To the clinic
AppointmentsMechelen-based biotech Galapagos NV has appointed Walid Abi-Saab to the role of Chief Medical Officer.
Pharmalink: Global chair
AppointmentsSpecialty pharma company Pharmalink AB has elected Maria Carell as Chair of the Board of Directors. Carell replaces Hilde Furberg, who will take over as Vice Chair.